Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2008.19.8853 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Paeoniflorin sensitizes imatinib mesylate-resistant chronic myeloid leukemia cells via the inhibition of Cyr61 production.
Anticancer Drugs
January 2025
Department of Laboratory Medicine, Fujian Medical University Union Hospital, Fuzhou, China.
Imatinib mesylate (IM) is a first-line therapy for chronic myeloid leukemia (CML) and exhibits good therapeutic effects, but not in all patients with CML owing to drug resistance. Our previous study showed that Cyr61 plays a key role in IM resistance in CML cells. Paeoniflorin (PF) is a bioactive compound isolated from the traditional Chinese medicine Paeonia lactiflora Pall that displays anticancer activity.
View Article and Find Full Text PDFSRC kinase drives multidrug resistance induced by KRAS-G12C inhibition.
Sci Adv
December 2024
Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Direct targeting of the -mutant protein using covalent inhibitors (G12Ci) acts on human non-small cell lung cancer (NSCLC). However, drug resistance is an emerging concern in this approach. Here, we show that MRTX849, a covalent inhibitor targeting the mutation, leads to the reactivation of the mitogen-activated protein kinase signaling pathway in MRTX849-resistant NSCLC and pancreatic ductal adenocarcinoma.
View Article and Find Full Text PDFSKI-606, a Src inhibitor, ameliorates benzene-induced hematotoxicity via blocking ROS/Src kinase-mediated p38 and Akt signaling pathways.
Ecotoxicol Environ Saf
November 2024
Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China; Institute of Hematology, Wenzhou Medical University, Wenzhou, Zhejiang, China; Wenzhou Key Laboratory of Hematology, Wenzhou, Zhejiang, China; Laboratory Animal Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Electronic address:
Exposure to benzene causes acute myelosuppression and other hematologic disorders. However, the detailed mechanism by which benzene exerts its severe hematotoxicity and potential treatments still require further deciphering and exploration. Herein, we found that hydroquinone (HQ), a main benzene metabolite, significantly increased intracellular reactive oxygen species (ROS) formation and subsequently caused damage to DNA, leading to impaired colony formation capacity and induction of apoptosis in human hematopoietic stem/progenitor cells (HSPCs) in vitro.
View Article and Find Full Text PDFTyrosine kinase inhibitors (TKIs) targeting the BCR-ABL fusion protein, such as imatinib (Gleevec), have revolutionized targeted cancer therapies. However, drug resistance and side effects, particularly those affecting hemostasis, continue to pose significant challenges for TKI therapies. As tyrosine kinases serve pivotal roles in platelet hemostatic function, we investigated the potential impact of both established and emerging ABL TKIs on human platelet activities Our study included standard-of-care agents (e.
View Article and Find Full Text PDFDasatinib-Induced Bilateral Chylothorax: A Case Report.
Cureus
September 2024
Internal Medicine, AdventHealth Waterman, Tavares, USA.
Article Synopsis
- Dasatinib is a medication used to treat Philadelphia-positive chronic myeloid leukemia (CML), but it can cause complications, one of which is chylothorax—a buildup of fluid in the chest.
- A case of a 79-year-old female who developed acute breathing issues while on dasatinib revealed bilateral chylothorax, leading to the conclusion that the medication was likely the cause, as no other risk factors were found.
- After stopping dasatinib and switching to bosutinib, along with a low-fat diet, the patient showed no recurrence of chylothorax six months later, highlighting the need for awareness and management strategies regarding this complication
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!